Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | VP, Finance and Controller | March 20, 2026 | March 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date March 20, 2026 · Filed March 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,055 |
Ending reported balance
After 2026-03-20 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-20 · Exercise / conversion · Acquired 865 · Balance 47,224 F1: Restricted Stock Units convert into common stock on a one-for-one basis. Row 2 · 2026-03-20 · Sale · Disposed 310 · Balance 46,914 F2: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Row 3 · 2026-03-20 · Exercise / conversion · Acquired 221 · Balance 47,135 F1: Restricted Stock Units convert into common stock on a one-for-one basis. Row 4 · 2026-03-20 · Sale · Disposed 80 · Balance 47,055 F2: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,119 |
Reported balance
After 2026-03-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-20 · Exercise / conversion · Disposed 865 · Balance 12,119 F1: Restricted Stock Units convert into common stock on a one-for-one basis. F3: The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,087 |
Reported balance
After 2026-03-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-20 · Exercise / conversion · Disposed 221 · Balance 3,087 F1: Restricted Stock Units convert into common stock on a one-for-one basis. F4: The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units convert into common stock on a one-for-one basis.
F2: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F3: The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.
F4: The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2026 Filed Mar 24, 2026 18:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionRestricted Stock Units · Derivative | 221 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-122341 · ownership.xml · derivative · entry 6 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,087 Underlying: Common Stock · 221 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. F4 · derivative.expiration_date: The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 18:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionRestricted Stock Units · Derivative | 865 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-122341 · ownership.xml · derivative · entry 5 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,119 Underlying: Common Stock · 865 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. F3 · derivative.expiration_date: The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 18:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 80 | $8.61 | $688.80 |
DisclosureSEC source: 0001193125-26-122341 · ownership.xml · nonDerivative · entry 4 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,055 F2 · kind: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 18:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 221 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-122341 · ownership.xml · nonDerivative · entry 3 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 18:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 310 | $8.61 | $2,669.10 |
DisclosureSEC source: 0001193125-26-122341 · ownership.xml · nonDerivative · entry 2 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,914 F2 · kind: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 18:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 865 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-122341 · ownership.xml · nonDerivative · entry 1 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| December 20, 2025 Filed Dec 23, 2025 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionRestricted Stock Units · Derivative | 220 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-331299 · ownership.xml · derivative · entry 6 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,308 Underlying: Common Stock · 220 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. F4 · derivative.expiration_date: The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. Read SEC document |
| December 20, 2025 Filed Dec 23, 2025 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionRestricted Stock Units · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-331299 · ownership.xml · derivative · entry 5 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,984 Underlying: Common Stock · 866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. F3 · derivative.expiration_date: The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company. Read SEC document |
| December 20, 2025 Filed Dec 23, 2025 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 79 | $8.68 | $685.72 |
DisclosureSEC source: 0001193125-25-331299 · ownership.xml · nonDerivative · entry 4 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,359 F2 · kind: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| December 20, 2025 Filed Dec 23, 2025 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 220 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-331299 · ownership.xml · nonDerivative · entry 3 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
| December 20, 2025 Filed Dec 23, 2025 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 310 | $8.68 | $2,690.80 |
DisclosureSEC source: 0001193125-25-331299 · ownership.xml · nonDerivative · entry 2 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,218 F2 · kind: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| December 20, 2025 Filed Dec 23, 2025 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-331299 · ownership.xml · nonDerivative · entry 1 Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.